VigiBase

VigiBase
Name	VigiBase
Producer	World Health Organization
Discipline	Pharmacovigilance
Country	Switzerland
Established	1968
Provider	Uppsala Monitoring Centre

VigiBase is the global pharmacovigilance database maintained by the Uppsala Monitoring Centre under the auspices of the World Health Organization. It aggregates individual case safety reports submitted from national pharmacovigilance centres and regulatory authorities worldwide, supporting signal detection, risk assessment, and public health interventions. The resource interfaces with international regulatory frameworks and pharmacovigilance programs across continents including contributions from agencies such as the European Medicines Agency, Food and Drug Administration, and regional centres in India, Brazil, and South Africa.

Overview

VigiBase contains post-marketing safety reports for medicinal products, vaccines, and biologics collected from national centres such as the Medicines and Healthcare products Regulatory Agency, Health Canada, and the Pharmacovigilance Programme of India. The database supports analytics used by organizations including the European Commission, Pan American Health Organization, African Union, and academic partners at institutions like Harvard University and University of Oxford. Its methodology interacts with standards from bodies such as the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use and tools developed by research consortia including the Observational Health Data Sciences and Informatics community.

History and development

The initiative traces to early WHO efforts in the 1960s following high-profile drug safety events involving products reviewed by regulators like the United Kingdom Medicines Board and influenced policy debates in forums such as the World Health Assembly. The Uppsala Monitoring Centre was established to host the global database and has evolved alongside milestones in pharmacovigilance exemplified by the creation of the European Medicines Agency and regulatory transformations led by authorities such as the Food and Drug Administration. Over decades, technological upgrades incorporated methods from informatics groups at Massachusetts Institute of Technology and Stanford University and integrated coding standards influenced by the World Health Assembly resolutions and WHO Collaborating Centres.

Data content and structure

Entries in the database are individual case safety reports that include coded terms from dictionaries like Medical Dictionary for Regulatory Activities and link to product information holders such as Pfizer, Johnson & Johnson, AstraZeneca, Moderna, and GlaxoSmithKline. The structure captures reporter type from institutions such as Mayo Clinic and Johns Hopkins Hospital, patient demographics referencing national identifiers used in systems like National Health Service (England), and event narratives comparable to case reports published in journals like The Lancet and New England Journal of Medicine. Data fields enable signal detection algorithms analogous to methods developed in research at Imperial College London and analytic frameworks used by the European Centre for Disease Prevention and Control.

Access and use

Access is provided to WHO member states and authorised stakeholders including national regulatory authorities such as Federal Institute for Drugs and Medical Devices and pharmacovigilance centres affiliated with organizations like Centers for Disease Control and Prevention and Public Health England. Researchers from universities such as Columbia University and University of Melbourne may obtain controlled access under agreements similar to data-sharing arrangements used by the Global Fund and humanitarian agencies like Médecins Sans Frontières. Pharmaceutical companies and marketing authorisation holders interact with outputs through regulatory submissions to entities like the European Medicines Agency and litigation contexts in courts such as the International Court of Justice rarely, while public summaries are issued via WHO and partner communications including releases at forums like the World Health Assembly.

Governance and data privacy

Governance is overseen by the World Health Organization in consultation with the Uppsala Monitoring Centre and national pharmacovigilance programmes such as those coordinated by Health Canada and the Therapeutic Goods Administration (Australia). Data privacy frameworks reference international instruments such as the General Data Protection Regulation and national laws enacted by parliaments like the Parliament of the United Kingdom and United States Congress, and align with ethical guidance from bodies such as the Council for International Organizations of Medical Sciences. Agreements specify anonymisation practices comparable to protocols used by World Bank and United Nations Children's Fund data operations.

Impact and applications

VigiBase has contributed to regulatory decisions, safety labeling changes, and public health alerts issued by agencies including the European Medicines Agency, Food and Drug Administration, and national ministries of health in Japan, Germany, and France. Its data underpin research published in periodicals such as BMJ and JAMA and inform vaccine safety assessments during campaigns led by Gavi, the Vaccine Alliance and emergency responses coordinated with World Health Organization incident management systems. Applied use cases include signal detection methodologies adopted by pharmacovigilance networks in Nigeria and Argentina, post-marketing surveillance studies with collaborators at University of Toronto and Karolinska Institutet, and contributions to global safety policy dialogues at assemblies like the World Health Assembly.

Category:Pharmacovigilance